A big challenge in treating breast cancer is discerning slow-growing tumors from aggressive ones; that's key because different types require very different treatment. While tests can spot one of the aggressive types—HER-2 positive—the results often take a couple of weeks, and they're not always accurate, say experts. A new test approved this summer by the FDA may prove more useful: SPOT-Light checks biopsied tissue for copies of the HER-2 gene—an indication of whether the tumor will be vulnerable to the powerful anticancer drug Herceptin. A pathologist stains the tumor tissue with a chemical that causes HER-2 genes to change color. This test is potentially more accurate than older versions and can be done at the doctor's office or a local lab on conventional equipment.
Grow your life! Get an exclusive look at Oprah's new farm, uncover 28 fresh ideas for happier living, and learn Bob Greene's top secret to eating smarter. Plus, find out how you can win a trip to Hawaii to have lunch with Oprah!